Abstract
A case of diffuse scleroderma in a 56-year-old woman who received paclitaxel for the treatment of a metastatic ovarian cancer is presented. The clinical cutaneous alterations, as well as the capillaroscopic and histological findings, were indistinguishable from those encountered in definite systemic sclerosis (SSc). In contrast to SSc, Raynaud's phenomenon and cutaneous calcinosis were absent and antinuclear antibodies were negative. The temporal relationship between the onset of skin involvement and administration of the drug may indicate an effect of paclitaxel.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 11 January 2002 / Accepted: 10 June 2002
Rights and permissions
About this article
Cite this article
De Angelis, R., Bugatti, L., Cerioni, A. et al. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer. Clin Rheumatol 22, 49–52 (2003). https://doi.org/10.1007/s10067-002-0635-8
Issue Date:
DOI: https://doi.org/10.1007/s10067-002-0635-8